Vaxcyte (PCVX) Q4 2025 earnings summary

Executive summary

• Achieved significant progress in clinical, manufacturing, and commercial readiness for the PCV franchise, with multiple late-stage clinical trials underway and a robust financial position to support future milestones.

• Advanced VAX-31 adult Phase 3 clinical program with three ongoing studies to support a planned BLA submission, finalized in consultation with the FDA.

• Completed enrollment in VAX-31 infant Phase 2 dose-finding study; topline data expected by mid-2027.

• Expanded adult Breakthrough Therapy designation for VAX-31 to include pneumonia prevention.

• Strengthened leadership team and board with experienced industry executives.

Financial highlights

• Cash, cash equivalents, and investments totaled $2.44 billion as of December 31, 2025, down from $3.13 billion at year-end 2024.

• Raised $600.2 million (or $632.5 million) in net proceeds from a public equity offering in February 2026, further strengthening the balance sheet.

• Net loss for 2025 was $766.6 million, compared to $463.9 million in 2024.

• R&D expenses rose to $794.3 million in 2025 from $476.6 million in 2024, driven by increased development and manufacturing activities.

• Completed capital-intensive build-out of a dedicated manufacturing facility; future related costs will be expensed rather than capitalized.

Outlook and guidance

• Cash runway expected to last through at least the end of 2028, supporting execution of multiple clinical, regulatory, and manufacturing milestones.

• Topline data from OPUS-1 Phase 3 adult trial expected in Q4 2026; OPUS-2 and OPUS-3 results expected in H1 2027.

• Expect to announce infant VAX-31 phase II data (primary and booster series) by mid-2027.

• Plan to initiate a phase I study for VAX-A1 in adults in 2026.